Seymour Phase Ⅱ clinical study analyzed the drug navitoclax (apoptosis regulatory proteins Bcl-2 inhibitor targeting high affinity) for 27 patients with relapsed chronic lymphocytic leukemia (CLL) efficacy, patients were treated prior to high intensity treatment, in the median age was 70 years, up until disease progression or intolerance. The results show that, navitoclax does have clinical efficacy in patients with objective response rate was 33%, 19 cases of peripheral blood lymphocyte count decreased> 50%, 12 cases were treated with adenovirus reduced more than 50% the size of lymph nodes.
Drug treatment of CLL paying off navitoclax
ReplyDeleteSeymour Phase Ⅱ clinical study analyzed the drug navitoclax (apoptosis regulatory proteins Bcl-2 inhibitor targeting high affinity) for 27 patients with relapsed chronic lymphocytic leukemia (CLL) efficacy, patients were treated prior to high intensity treatment, in the median age was 70 years, up until disease progression or intolerance. The results show that, navitoclax does have clinical efficacy in patients with objective response rate was 33%, 19 cases of peripheral blood lymphocyte count decreased> 50%, 12 cases were treated with adenovirus reduced more than 50% the size of lymph nodes.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
GW 5074
AZ 628
ZM 336372
SP600125
CC-401 HCl
JNK-IN-8
AS 602801
SB 203580
SB 202190
Doramapimod